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Chemokines in depression in health and in inflammatory
illness: a systematic review and meta-analysis
SP Leighton1,5, L Nerurkar2,5, R Krishnadas3, C Johnman1, GJ Graham2 and J Cavanagh4
Inflammatory illness is associated with depression. Preclinical work has shown that chemokines are linked with peripheral–central
crosstalk and may be important in mediating depressive behaviours. We sought to establish what evidence exists that differences
in blood or cerebrospinal fluid chemokine concentration discriminate between individuals with depression and those without.
Following PRISMA guidelines, we systematically searched Embase, PsycINFO and Medline databases. We included participants with
physical illness for subgroup analysis, and excluded participants with comorbid psychiatric diagnoses. Seventy-three studies met
the inclusion criteria for the meta-analysis. Individuals with depression had higher levels of blood CXCL4 and CXCL7 and lower
levels of blood CCL4. Sensitivity analysis of studies with only physically healthy participants identified higher blood levels of CCL2,
CCL3, CCL11, CXCL7 and CXCL8 and lower blood levels of CCL4. All other chemokines examined did not reveal significant
differences (blood CCL5, CCL7, CXCL9, CXCL10 and cerebrospinal fluid CXCL8 and CXCL10). Analysis of the clinical utility of the
effect size of plasma CXCL8 in healthy individuals found a negative predictive value 93.5%, given the population prevalence of
depression of 10%. Overall, our meta-analysis finds evidence linking abnormalities of blood chemokines with depression in humans.
Furthermore, we have demonstrated the possibility of classifying individuals with depression based on their inflammatory
biomarker profile. Future research should explore putative mechanisms underlying this association, attempt to replicate existing
findings in larger populations and aim to develop new diagnostic and therapeutic strategies.
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INTRODUCTION
Depressive disorders are the third leading cause of years lost to
disability worldwide, rising to second among 15–49 year olds. This
burden has increased over the past 25 years.1 Our current
understanding of depression and its diagnosis and treatment
centres around the monoamine hypothesis. Yet, 30% of patients
fail to respond to such anti-depressants and among responders
only a third attain remission.2 This high rate of treatment failure
likely reflects an incomplete understanding of the pathogenesis of
depressive disorders. Efforts are focused on effective stratification
of a heterogeneous population and novel therapeutic avenues.
Over the past quarter century, an increasingly compelling body
of evidence has emerged linking inflammation to depression.3–10
Broadly, this evidence stems from four main observations:
1. A third of those with depression show elevated inflammatory
cytokines, in the absence of medical illness.
2. Inflammatory illnesses are associated with greater rates of
depression than noninflammatory illnesses.
3. Up to 40% of patients treated with cytokine therapy develop
clinical depression.
4. Higher baseline inflammation is associated with a lack of
response to anti-depressant treatment.
Preclinical work has identified chemotactic cytokines (chemo-
kines) as an important group of molecules in both the immune
system, where they act to coordinate immune cells and attract
them to sites of ongoing inflammation, and the nervous system.
Evidence indicates they play a role in neuron–glia communication,
synaptic transmission, neurogenesis, neurodevelopment and
plasticity and this was recently extensively reviewed by Stuart
et al.11 Because of their role in cellular migration and immune
coordination, chemokines are prime candidates for linking
peripheral and central inflammation and orchestrating neuroin-
flammatory crosstalk. D’Mello et al.12 and Wohleb et al.13
highlighted the role for chemokines, particularly CCL2, in these
processes in their studies of monocytic migration. Despite being
widely expressed in the noninflamed adult brain,14 it is only in
recent years that their role in neuropsychiatric disease has been
explored more extensively. Recent studies have implicated CCL2,
CCL3 and CXCL10 in modifications of neuronal transmission and
alterations in cognitive function,15–17 and the neuromodulatory
functions of other chemokines have been reviewed elsewhere.18,19
Several chemokines, including CXCL8 and CXCL10, have been
associated with alterations in neuroendocrine regulation and
hypothalamic–pituitary–adrenal axis function.20,21 The CXCL12–
CXCR4 axis has been repeatedly identified as having a role in
neurogenesis.22–24 Finally, crosstalk between CX3CR1 and CX3CL1
appears to be a critical pathway for communication between
microglia and neurons during both physiological and pathological
states.24,25 Alterations in neurotransmitter and hypothalamic–
pituitary–adrenal axis function and reductions in neurogenesis are
consistently associated with depressive pathologies.26–29 As such,
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these data provide compelling evidence of a possible role for the
chemokine molecular family in the pathogenesis of depression.
Existing biomarker studies of chemokines in depression are
often underpowered, of disparate methodologies and are fre-
quently conflicting. Chemokine nomenclature is notoriously difficult
despite standardisation into a unified format. Ensuring a complete
coverage, especially of older literature, can be challenging. Eyre
et al.30 recently undertook a meta-analysis in the field and
encountered such issues that limited their interpretation to only
two of the most commonly studied chemokines, CCL2 and CXCL8.
Encouragingly, even within the past few months the field
continues to grow. However, the issues encountered by Eyre
et al.30 remain. Aiming to be pragmatic, clinically relevant and
allowing for the current state of the field, we set out to be as
comprehensive as possible while still using high-quality meta-
analytical techniques. We primarily achieved this aim through
extensive search terms utilising as many possible variant
chemokine names as possible.
In this paper, we lay out the results of our meta-analysis and
frame them within the context of the current animal and human
literature on inflammatory disease and depression, providing
evidence for the role of chemokines in depression and identifying
gaps in the literature to inform future research.
Our primary outcome:
● Do differences in blood or cerebrospinal fluid (CSF) chemokine
concentration discriminate between those with and those
without depression?
Our secondary outcomes:
● Do differences in blood or CSF chemokine concentration discrimi-
nate between those with and those without depression only in a
healthy subgroup, or only in a subgroup with physical illness?
● Are differences in blood chemokine concentration more
apparent in plasma or serum?
● Are higher-quality studies more likely to identify subgroup
differences?
MATERIALS AND METHODS
Data sources
We (SPL and LN) searched Embase, PsycINFO and Medline up to
5 March 2016. We manually checked references cited in the
systematically searched articles. In an effort to avoid publication
bias we included non-English language studies and grey literature
(for example, conference abstracts). We used a broad but highly
structured search strategy based around the PICOS framework,
our Population is humans, the Intervention/Exposure is depres-
sion, the Comparison is no depression, the Outcome is change in
blood or CSF chemokines, and the Study design included any type
of study design. Keywords for the search included various
combinations of terms for depression, depressive disorders and
depression research scales, and both historical and current
chemokine names. Extensive use of wildcards, truncation and
Boolean operators was implemented to allow for variant names
(for example, CCL2 alternate search terms (monocyte chemotactic
protein#1 or monocyte chemotactic protein-1 or mcp#1 or mcp-1
or small inducible cytokine a2 or gdcf#2 or gdcf-2 or hc11 or
hsmcr30 or mcaf or cmc#cf or smc-cf). The full search strategy is
available in the Supplementary Materials.
Study selection
Studies were selected for data extraction and analysis based on
the following inclusion criteria: (1) original research studies
measuring blood or CSF chemokine concentrations in depressed
and nondepressed subjects; (2) subjects met depression criteria
based on a conventional psychiatric classification system or
recognised depression rating scale (see search strategy); (3)
control subjects did not meet said criteria for depression; (4) in
an attempt to be pragmatic and increase real-world applicability,
we included studies with participants suffering from physical
comorbidity (any comorbidity with an established inflammatory
component or sequelae) if the comorbidity was comparable and
identifiable between cases and controls to allow for subgroup
analysis (see characteristics of included studies table).
We excluded studies based on the following criteria: (1)
participants had a comorbid or additional psychiatric diagnosis
that would exclude or confound depression as per conventional
psychiatric nosological thinking (that is, mania, bipolar disorder,
schizophrenia or other nondepressive affective or nonaffective
psychosis); (2) in vitro and nonhuman studies; (3) studies looking
at stimulated levels of cytokines as they reflect the consequences
of immune challenge as opposed to basal immune activity; (4)
studies including participants who had not yet reached puberty.
Data extraction
Two independent reviewers (SPL and LN) used a custom data
extraction template adapted from the Cochrane checklist of items
(see Supplementary Materials). Non-English language studies were
translated. For meta-analysis, mean (± s.d.) chemokine concentra-
tions for each group of depressed and nondepressed control
subjects were extracted. We also sought data that were missing
from the original reports through correspondence with the
investigators. When correspondence was not successful, alternate
techniques were used for data extraction. If data were presented
as median (interquartile range), we used an established approx-
imation method to estimate mean ( ± s.d.);31 if data were
presented only in graphical format, we used Engauge data
extraction software;32 if presented as raw data with chemokine
concentration and depression rating scale score, participants were
dichotomised based on established cutoff scores for ‘caseness’ for
the relevant rating scale and mean( ± s.d.) calculated; if different
severities of depression were presented separately, means and s.d.
were combined based on subgroup number. Such calculations
were carried out within Microsoft Excel 2013. Disagreements
regarding inclusion were settled by consensus.
Quality assessment
This meta-analysis was carried out according to Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines. To assess quality we adapted the New-
castle–Ottawa Quality Assessment Scale for observational studies
as recommended by the Cochrane Collaboration, together with
the Cochrane common classification scheme for bias, with
additional points for adjusting or matching important confoun-
ders identified from the literature (smoking, circadian rhythm
(time of blood draw), body mass index, age, sex and medications),
whether the source was a peer-reviewed article or an abstract, and
whether we used Engauge data extraction software or data
approximation giving a total score out of 17 (Supplementary Table
1). Given the small number of studies in the field, we included all
accepted studies in our meta-analysis but where possible
conducted sensitivity analysis only including studies that scored
greater than or equal to the median quality score (⩾12/17),
considered to be a low risk of bias.
Statistical analysis
We used RevMan 5.3 (ref. 33) for analysis. To be conservative, we
used weighted standardised mean differences (SMD) between
controls and cases to calculate the effect size of each study given
the heterogeneity of the assays used to measure the chemokines
(for example, enzyme-linked immunosorbent assay, microarray)
and, for blood chemokines, that of the modality in which they
were measured (for example, serum, plasma). Weighted SMD and
95% confidence intervals (CIs) were then calculated using a
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random effects inverse variance model. This meta-analytic method
includes both within-study variance and between-studies varia-
tion in the estimate of the uncertainty of results. Unlike a fixed
effects model, a random effects model assumes that the under-
lying true effects vary from one study to another. A random effects
model is more conservative and is chosen if significant hetero-
geneity is expected.
We measured statistical heterogeneity using the I2 statistic for
statistical variation across studies—values of 25% are low, 50%
moderate and 75% high. The presence of significant hetero-
geneity suggests variability in the characteristics of the trials.
Likely sources of heterogeneity including presence or absence of
physical illness among participants, modality of blood chemokine
measurement, sex, possible outliers and quality score were
investigated by sensitivity analysis where data allowed.
Additional sensitivity analyses were performed for chemokines
that attained statistical significance to further explore hetero-
geneity. Where numbers allowed, we assessed: only studies that
used a Diagnostic and Statistical Manual of Mental Disorders
(DSM) Major Depressive Disorder (MDD) diagnosis, specific
subtypes of illness, only articles, removing Fontenelle 201234
where subjects had comorbid obsessive–compulsive disorder,
removing studies where alternative methods for data extraction
were required and only studies that matched for specific
confounders (age, gender, body mass index, smoking, circadian
rhythm of blood sampling and medication).
The possibility of publication bias was tested by visual
inspection of funnel plots and by testing for asymmetry using
the Egger weighted regression test within R35 using the metafor
package.36 The nonparametric (rank-based) trim and fill data
augmentation technique was used within R using metafor to
estimate the number of studies missing from a meta-analysis
because of the suppression of the most extreme results on one
side of the funnel plot. The method then augments the observed
data so that the funnel plot is more symmetric and its effect on
the results was assessed.
To establish whether the effect sizes found in the meta-analysis
had clinical utility, we examined the classification accuracy of
CXCL8 in robustly discriminating cases from controls. This was
possible because of the large numbers of participants eligible for
inclusion, the equal distribution of cases and controls and the
significant SMD with narrow confidence intervals in the plasma
CXCL8 meta-analysis of healthy participants. We simulated CXCL8
data for n cases and n controls in R based on the SMD (Hegde’s g)
derived from meta-analysis of plasma CXCL8 concentration in
participants without comorbid physical illness, together with the
number of cases and of controls, based on a known mean and s.d.
of plasma CXCL8 in a normal healthy population (mean:
6.911 pg ml− 1; s.d.: ± 3.818 pg ml− 1) given the assumption of a
normal distribution as stated by the central limit theorem using
the code outlined by Fried and Kievit37 (Supplementary Figure 1).
For the analysis, we estimated the classification accuracy using a
logistic regression classifier with a 10-fold cross-validation
procedure using Weka 3 Data Mining Software.38 In 10 (n) fold
cross-validation, data are divided into 10 folds. A logistic classifier
is built using n-1 folds, leaving out one fold. The built classifier is
then tested on the left-out fold, and the classification accuracy is
calculated. The above procedure is repeated n times by leaving
out one-fold each time. Finally, the cross-validation classification
accuracy is the average accuracy across all the left-out folds. In
addition, we report the sensitivity, specificity, positive predictive
value (PPV) and negative predictive value (NPV) of CXCL8. Here,
sensitivity measures the proportion of positives that are correctly
identified as such; in this case the percentage of patients who are
correctly identified as having depression. Specificity measures the
proportion of negatives that are correctly identified, or the
percentage of healthy controls who are correctly identified as
controls. PPV represents the proportion of individuals with
depression among all those who tested positive, and NPV
represents the proportion of healthy controls among those who
tested negative. The PPV and NPV are sensitive to the prevalence
of the disease. These were calculated with a conservative estimate
of 10% prevalence of MDD in the general population. These
quantities are computed as follows:
Sensitivity ¼ True Positive
True Positiveþ False Negative
Specif icity ¼ True Negative
False Positiveþ True Negative
Accuracy ¼ True Positiveþ True Negative
True Positiveþ False Positiveþ False Negativeþ True Negative
PPV ¼ sensitivityð Þðnumber of casesÞ
sensitivityð Þ number of casesð Þ þ 1 - specif icityð Þðnumber of controlsÞ
NPV ¼ specif icityð Þðnumber of controlsÞ
specif icityð Þ number of controlsð Þ þ 1- sensitivityð Þðnumber of casesÞ
RESULTS
Study inclusion
The utilisation of the PRISMA guidelines and a systematic search of
electronic databases yielded a total of 8497 studies. No additional
studies were identified through manual searching of references.
After removal of duplicates, 7440 titles were reviewed of which
4105 were excluded. Of the 3335 abstracts reviewed, 2981 were
excluded. In all, 354 full texts were reviewed of which 73 met
criteria for inclusion in our meta-analysis34,39–109 (Figure 1 and
Supplementary Table 2).
Specific chemokines
CCL2. A total of 21 studies including 4688 participants (1507
cases, 3181 control) were included in the CCL2 analysis. Blood
Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews
and Meta-Analyses) flowchart showing study selection process and
number of studies from each database.
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Figure 2. Forest plot of CCL2 (a), CCL3 (b), CCL4 (c) and CCL11 (d) chemokine levels in plasma and serum of depressed and not depressed
patients.
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Figure 3. Forest plot of CXCL4 (a), CXCL7 (b) and CXCL8 (c) chemokine levels in plasma and serum of depressed and not depressed patients.
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CCL2 measurements were significantly higher in depressed
subjects compared with controls (SMD=0.21; 95% CI: 0.02–0.40;
P= 0.03; Figure 2). Significant heterogeneity was observed in the
included studies (I2 = 81%; Po0.00001). Evidence of asymmetry
was present in the funnel plot (Supplementary Figure 2) and
Egger’s test demonstrated that this was significant (P= 0.0071);
despite this, trim and fill analysis did not impute any missing
studies.
Sensitivity analyses demonstrated that in studies with physically
healthy participants there was a significant difference in blood
CCL2, similar to that observed across all studies (SMD=0.26; 95%
CI: 0.01–0.51; P= 0.04; Figure 2). Studies in the presence of illness
did not reveal a significant difference. Comparisons of plasma and
serum measurements revealed a significant difference in serum
(SMD= 0.33; 95% CI: 0.09–0.58; P= 0.007), but not plasma. Analysis
of studies with a low risk of bias did not retain statistical
significance. Further details of analysis can be found in
Supplementary Table 2.
CCL3. A total of 6 studies including 510 participants (268 cases,
242 controls) were included in the CCL3 analysis. There was no
significant difference between blood CCL3 measurements in
depressed and control subjects (SMD=0.33; 95% CI: − 0.06 to
0.71; P= 0.10; Figure 2). Significant heterogeneity was observed
across the included studies (I2 = 76%; P= 0.0008). There was no
obvious asymmetry in the funnel plot (Supplementary Figure 3)
and Egger’s test was not significant (P= 0.5472).
Sensitivity analyses demonstrated that in studies with physically
healthy participants there was a significant increase in blood CCL3
between depressed and control subjects (SMD=0.48; 95% CI:
0.20–0.76; P= 0.0007). Neither plasma nor serum retained
significance alone. Analysis of studies with a low risk of bias
(n= 4) also demonstrated a significant difference between groups
(SMD= 0.58; 95% CI: 0.35–0.82; Po0.00001). Further details of
analysis can be found in Supplementary Table 3.
CCL4. A total of 5 studies including 507 participants (242 cases,
265 controls) were included in the CCL4 analysis. Blood CCL4
measurements were significantly lower in depressed subjects
compared with controls (SMD=− 0.31; 95% CI: − 0.49 to − 0.13;
P= 0.0007; Figure 2). Evidence of heterogeneity across studies was
not present (I2 = 0%; P= 0.85). There was no obvious asymmetry in
the funnel plot (Supplementary Figure 4) and Egger’s test was not
significant (P= 0.5548).
Sensitivity analyses demonstrated that in studies with physically
healthy participants there was a significant difference in blood
CCL4, similar to that observed across all studies (SMD=− 0.32; 95%
CI: − 0.54 to − 0.10; P= 0.005). Comparisons of plasma and serum
measurements revealed a significant difference in serum (SMD=
− 0.33; 95% CI: − 0.54 to − 0.12; P= 0.002), but not plasma. All
healthy studies for CCL4 were considered to have low risk of bias,
and therefore further sensitivity analysis was not performed.
Further details of analysis can be found in Supplementary Table 4.
CCL11. A total of 7 studies including 454 participants (230 cases,
224 controls) were included in the CCL11 analysis. There was no
significant difference between blood CCL11 measurements in
depressed and control subjects (Figure 2). Moderate heterogene-
ity was observed in the included studies (I2 = 64%; P= 0.02). There
was evidence of possible asymmetry in the funnel plot
(Supplementary Figure 5). However, Egger’s test was not
significant (P= 0.4629).
Sensitivity analysis demonstrated that in studies with healthy
participants there was a significant increase in blood CCL11 in
depressed subjects compared with controls (SMD=0.44; 95% CI:
0.20–0.68; P= 0.0003). Neither plasma nor serum was significant
alone. Analysis of studies with a low risk of bias also demonstrated
a significant difference between groups (SMD=0.48; 95% CI: 0.22–
0.74; P= 0.0003). Further details of analysis can be found in
Supplementary Table 5.
CXCL4. A total of 11 studies involving 792 participants were
included in the blood CXCL4 meta-analysis. Blood CXCL4
measurements were significantly higher in depressed subjects
compared with controls (SMD= 1.03; 95% CI: 0.22–1.83; P= 0.01;
Figure 3). There was evidence of statistical heterogeneity across
the studies (I2 = 96%; Po0.00001). The funnel plot showed
evidence of asymmetry (Supplementary Figure 6). However, the
Egger’s test was not significant (P= 0.3541).
Sensitivity analysis using Karege 2005 serum values instead of
plasma values did not alter overall significance or statistical
heterogeneity but reduced the overall SMD (SMD= 0.82; 95% CI:
0.03–1.61; P= 0.04). Sensitivity analysis involving only studies with
physically healthy participants or only those with a physical illness
did not attain statistical significance. Neither plasma nor serum
was significant alone. Sensitivity analysis involving studies with a
low risk of bias did not retain statistical significance. Further details
of analysis can be found in Supplementary Table 6.
CXCL7. A total of 11 studies involving 771 participants were
included in the blood CXCL7 meta-analysis. Blood CXCL7
Figure 4. Receiver operating characteristic (ROC) curve based on
effect size for plasma CXCL8 in studies with healthy participants
gives an area under the curve of 64.5%.
Table 1. Summary table of effect estimates for blood chemokines
with nonsignificant findings between depressed and nondepressed
individuals
Chemokine Studies Participants Effect estimate (95% CI)
Blood (plasma/serum)
CCL5 7 251 − 0.10 (−0.59, 0.40)
CCL7 3 156 0.07 (−0.65, 0.79)
CXCL9 3 161 − 0.05 (−0.60, 0.49)
CXCL10 3 350 1.17 (−0.26, 2.61)
CSF
CXCL8 6 361 0.19 (−0.15, 0.54)
CXCL10 4 208 − 0.06 (−0.35, 0.22)
Abbreviations: CI, confidence interval; CSF, cerebrospinal fluid.
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measurements were significantly higher in depressed subjects
compared with controls (SMD= 0.63; 95% CI: 0.10–1.15; P= 0.02;
Figure 3). There was evidence of statistical heterogeneity across
the studies (I2 = 90%; Po0.00001). The funnel plot showed
evidence of asymmetry (Supplementary Figure 7). However, the
Egger’s test was not significant (P= 0.7837).
Sensitivity analysis involving only studies with physically healthy
participants demonstrated a significant increase in blood CXCL7
(SMD= 0.54, 95% CI: 0.30–0.77; Po0.00001). However, this was
not true for studies with only physically ill participants.
Furthermore, among studies with only healthy participants there
was no evidence of statistical heterogeneity (I2 = 0%; P= 0.56).
Comparisons of plasma and serum measurements revealed a
significant difference in plasma (SMD= 0.71; 95% CI: 0.05–1.37;
P= 0.04), but not serum. Sensitivity analysis involving studies that
demonstrated low risk of bias retained statistical significance for
the healthy subgroup (SMD= 0.52; 95% CI: 0.20–0.84; P= 0.001)
and borderline statistical significance overall (SMD=0.40; 95% CI:
0.00–0.80; P= 0.05). Further details of analysis can be found in
Supplementary Table 7.
CXCL8. A total of 40 studies involving 3788 participants were
included in the blood CXCL8 meta-analysis. Blood CXCL8
measurements were significantly higher in depressed subjects
compared with controls (SMD= 0.26; 95% CI: 0.06–0.46; P= 0.01;
Figure 3). There was evidence of statistical heterogeneity across
the studies (I2 = 84%; Po0.00001). The funnel plot showed
evidence of asymmetry (Supplementary Figure 8). However, the
Egger’s test was not significant (P= 0.1069). Removing the
potential outlier among the studies with participants with physical
illness, Lebedeva 2014,73 retained overall statistical significance
(SMD= 0.16; 95% CI: 0.00–0.32; P= 0.04).
Sensitivity analysis involving only studies with physically healthy
participants demonstrated a significant increase in blood CXCL8
(SMD= 0.26; 95% CI: 0.05–0.46; P= 0.01) but still with statistical
heterogeneity (I2 = 75%; Po0.00001). Comparisons of plasma and
serum measurements revealed a significant difference in plasma
(SMD= 0.57; 95% CI: 0.18–0.96; P= 0.004), but not serum. Given
the large number of studies, it was possible to conduct sensitivity
analysis for studies involving only female participants; this
retained statistical significance overall (SMD=0.51; 95% CI: 0.03–
1.00; P= 0.04) and among healthy participants only (SMD= 0.69;
95% CI: 0.06–1.33; P= 0.03). Sensitivity analysis involving studies
that demonstrated low risk of bias did not retain statistical
significance. Further details of analysis can be found in
Supplementary Table 8.
Based on the effect size for plasma CXCL8 in studies with only
physically healthy participants, CXCL8 produced a classification
accuracy of 62.1% (95% CI: 58.9–65.14%), with receiver operating
characteristic area under the curve of 64.5% (Figure 4); sensitivity
of 63.4% (95% CI: 59.01–67.65%) and specificity of 60.63% (95% CI:
56.1–64.99%). Based on a population prevalence of 10% (MDD in
the general population), the PPV was 15.18% and NPV was high at
93.71%.
Additional sensitivity analyses
Additional sensitivity analyses of CCL3, CCL4, CCL11, CXCL4 and
CXCL7 did not affect the significance of results. For CCL2,
significance of results was not affected except when including
only studies that matched for body mass index or for circadian
rhythm of blood sampling. For CXCL8, all additional sensitivity
analyses except removing Fontenelle 2012 resulted in a loss of
overall significance. CXCL8 studies using DSM MDD diagnoses or
those matching for age retained significance for healthy
participants. When looking at only cardiovascular illness, CXCL8
meta-analysis attained statistical significance (SMD= 0.80; 95% CI:
0.07–1.54; P= 0.03). Detailed results of additional sensitivity are
summarised in Supplementary Table 9.
Other chemokines
We also examined blood CCL5, CCL7, CXCL9 and CXCL10, and CSF
CXCL8 and CXCL10. However, no significant differences were
observed in these analyses. Details of the studies and the
calculated differences can be seen in Table 1.
DISCUSSION
Chemokine ligands and receptors are expressed throughout both
the developing and mature central nervous system,110,111 under
both physiological and inflammatory conditions. This meta-
analysis indicates that a number of these chemokines (CCL2,
CCL3, CCL4, CCL11, CXCL4, CXCL7 and CXCL8) when measured in
the blood discriminate between those with and without
depression.
Specifically, significant increases were seen in CCL2, CXCL4,
CXCL7 and CXCL8 and a decrease in CCL4 when comparing
depressed and nondepressed. Examining our secondary out-
comes, including only healthy participants showed additional
increases in CCL3 and CCL11, whereas CXCL4 lost significance.
There were no significant differences in chemokine levels when
restricting our analysis to only those with physical comorbidities,
implying that additional inflammatory change associated with
depression is masked by the raised profile associated with the
underlying physical disease. However, when looking at cardiovas-
cular illness alone CXCL8 attained statistical significance. Perhaps,
this finding is related to the reduction in heterogeneity with
analysing only one illness subtype. Analysis of studies measuring
in plasma versus serum did not reveal any particular pattern,
suggesting there was no specific advantage in using plasma rather
than serum in terms of differences detected. Finally, when
examining studies with a low risk of bias we found that effects
tended to be ameliorated or lose significance, suggesting that
higher-risk studies are greater contributors to the effect sizes
observed.
On comparing our findings with those observed in other meta-
analyses by Eyre et al.30 and Köhler et al.,112 significant increases in
CCL2 found in our study are similar. It is worth noting, however,
that significance for CCL2 seen in Köhler et al.112 did not remain
after exclusion of a study by Shen et al.113 We excluded this study
before meta-analysis because of its high risk of bias and our
inability to contact the authors. In contrast to either Eyre et al.30 or
Köhler et al.,112 we did note increases in CXCL8. In addition, when
including studies with only a low risk of bias, neither CCL2 nor
CXCL8 were significantly different in our meta-analysis, suggesting
that less methodologically rigorous studies may be contributing to
the differences we identified.
Although Köhler et al.112 did not identify alterations in CCL3, our
study indicated significant increases that were retained even
when considering only those studies with a lower risk of bias.
Another possible explanation for the differences in CCL2, CCL3
and CXCL8 findings between our study and the other meta-
analyses is that we identified a greater number of studies for
inclusion, possibly because of our more complete search strategy.
Finally, it is worth highlighting that we were able to analyse an
increased number of chemokines in this study, compared with
previous meta-analyses. Although this may be because of our
broad inclusion criteria, it highlights the need for comprehensive
search strategies when examining chemokine literature and the
strengths of using the multiple variant names of these molecules
when searching databases.
Our analysis suggests that the classification accuracy, receiver
operating characteristic area under the curve, sensitivity and
specificity of plasma CXCL8 in discriminating depressed subjects
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from controls is significantly better than 50% (chance). Because of
the low specificity of depressive mood symptoms, identification of
a test with high NPV that can discriminate MDD from other
conditions that have similar symptomatology could have potential
clinical utility. With a realistic population prevalence of major
depressive disorder of 10%, we found a high NPV of 93.71%. This
univariate test compares favourably with a 97.59% NPV estab-
lished via meta-analysis of major depression screening instru-
ments in primary care.114 We propose that accuracy would be
likely to improve with a multivariate approach, utilising a number
of blood and mood measures. In addition, replicating our CXCL8
meta-analysis using the complementary methodological approach
suggested by Fried and Kievit36 allows for a more accurate
interpretation of our results and adds to the validity of our
findings.
Several human studies point to relevant role for chemokines in
the biology of depression. In the brains (dorsal anterior cingulate)
of depressed suicides compared with sudden death matched
controls, Torres-Platas et al.115 showed that monocytes traffic to
the brain and congregate perivascularly in association with CCL2.
Similarly, Pantazatos et al.116 used RNA-sequencing on post-
mortem brain tissue (DLPFC-BA9) from MDD suicide (MDD-S) and
compared with MDD non-suicide and controls. The greatest
differences between MDD with and without suicide (that is, within
the MDD group) were in molecular pathways that related to
microglia and the immune system, in particular in genes for CCL2
and CCL4. The greatest difference between MDD and controls was
seen in the chemokine CXCL8. Pantazatos et al.116 have high-
lighted the issue of chemokine pleiotropy and this is germane to
the apparently counterintuitive finding of reduced levels of CCL4.
In their post-mortem tissue samples, Pantazatos et al.116 also
noted lower expression of CCL2 in the brains of MDD-S—in
contrast with Torres-Platas et al.115 who found raised levels in
MDD-S. However, the data in the literature varies here, with
measurements in different tissue compartments and different
patient groups contributing to sometimes opposing findings.
Interestingly, studies that have noted lower CXCL8, CCL2 and CCL4
have all been in groups exhibiting suicidal behaviour.63,117–119
Limitations
There are a number of limitations to this systematic review and
meta-analysis. We found that there was a reasonable risk of
publication bias for a number of analyses, particularly when
looking at funnel plots. Overall, a risk of reporting bias was
present. However, by contacting authors directly for data we hope
to have overcome the main issues associated with this. Strengths
are that by including multiple databases and following PRISMA
guidelines, it is unlikely that relevant studies were missed. In
addition, two independent reviewers assessed the quality and bias
of included studies.
In terms of individual studies, the quality was highly variable
with notable differences in controlling for confounders, the
mixture of plasma and serum used to measure the chemokines
and the lack of parsing of subtypes of depression, for example,
melancholic vs nonmelancholic.
Future directions
If the relationships between chemokine biology and the
neurobiology of depression are to be fully understood, then a
number of steps require to be followed. Longitudinal studies of
peripheral blood measures of chemokines would allow more than
the currently available single time snapshots and help to unpick a
state versus trait relationship with inflammatory biomarkers. Such
designs would also allow correlation with age groups, symptom
types and Research Domain Criteria profiles along with relation-
ships, if any, with treatment status.
More fundamental mechanistic research is essential if we are to
truly understand the role that chemokines play in the context of
sickness behaviour and longer-term models of inflammation in
preclinical models. Much of the work to date has focussed on the
role that chemokines play in normal neurodevelopment. The
extent to which chemokines play their part in orchestrating the
systemic inflammatory response is strongly indicative of an
important role in how this inflammatory response operates within
the central nervous system thus affecting behaviour. Furthermore,
unpicking inflammatory versus neuromodulatory functions and
the relationship between them will provide further insight into the
pathophysiological mechanisms of depressive disorders.
Summary
In this systematic review and meta-analysis of the available
literature, a number of chemokines were found to be altered in
depressed individuals. These chemokines are involved in both
neurobiological functions and with leukocyte trafficking and
recruitment known to be associated with depression.
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